March has officially arrived, which means Spring is finally just around the corner. When it comes to swapping one’s wardrobe ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

By Nqobile Dludla JOHANNESBURG (Reuters) -Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...